Stakeholder Opinions: Type 2 Diabetes in the UAE & Saudi Arabia Growth opportunities in fragmented markets


December 19, 2008
27 Pages - SKU: DFMN2069254
License type:
Countries covered: Saudi Arabia, United Arab Emirates

Introduction

This report focuses on the challenges of diverse and uncoordinated treatment paradigms for diabetes and the movement to rationalize efforts and establish best practice. Datamonitor uncovers the unique dynamics of the two largest diabetes markets in the GCC; including the impact of regulatory processes such as the healthcare reforms currently being undertaken.

Scope
  • Description and analysis of the uniqueness of the antidiabetic markets in the UAE and Saudi Arabia
  • Fragmented healthcare delivery in the UAE and Saudi Arabia presents opportunity for ramping up sales of generics and novel antidiabetic therapeutics.
  • Commercial implications of Datamonitor's extensive findings and our recommendations to maximize sales in these two markets.
Highlights

Diabetes has reached near-epidemic proportions in the UAE and Saudi Arabia, with nearly one out of every five individuals suffering from diabetes in the UAE. In Saudi Arabia, the prevalence is expected to rise to between 40-50% by 2020.

The delivery of treatment for diabetes is highly fragmented, and leads to sub-optimal treatment for patients in the two countries. The fragmentation is caused by a wide variety of issues due to systemic deficiencies, regulatory changes and socio-economic factors.

Datamonitor has explained the commercial implications of its findings and developed recommendations for healthcare firms and regulators to address the many unmet needs in the treatment of diabetes and to ramp up sales and share of market in both UAE and Saudi Arabia.

Reasons to Purchase
  • Gain an in-depth understanding of the two largest diabetes markets in the GCC; a strategic growth area for healthcare firms.
  • Increase share of the market by effectively targeting the different segments of the population and demands; branded or generic antidiabetic agents.
  • Maximize current and future revenue streams by targeting the numerous growth opportunities identified by Datamonitor.



More Drug Discovery reports by Datamonitor

Pipeline: Colorectal Cancer by Datamonitor
IntroductionTargeted therapies continue to dominate the colorectal cancer pipeline. With two new approvals in 2012, drug developers must now move away from anti-VEGF drugs toward ...
The Osteoporosis Market Outlook to 2021 by Datamonitor
IntroductionThe seven major markets are characterized by an aging population and hence the incidence of osteoporosis will increase accordingly. The increase in patient numbers, however, ...
The Osteoporosis Market Forecast to 2021 by Datamonitor
IntroductionThe seven major markets are characterized by an aging population and hence the incidence of osteoporosis will increase accordingly. The increase in patient numbers, however, ...
Pipeline: Renal Cell Cancer by Datamonitor
IntroductionSeven targeted therapies are available for the treatment of RCC but there is still considerable pipeline activity. Currently approved targeted therapies have been unable to ...
See all reports like this >>

More United Arab Emirates reports

Country Risk Service United Arab Emirates January 2013 Updater by The Economist Intelligence Unit
Country Risk Service is a comprehensive two-year forecasting service that monitors risks in 100 key emerging markets. It is designed for commercial bankers, institutional investors ...
D&B Country RiskLine Report: The United Arab Emirates by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
United Arab Emirates: Country Profile by MarketLine
INTRODUCTIONThis report provides a detailed analysis on the United Arab Emirates (UAE), providing an overview of its political, economic and business environment, represented both textually ...
See all reports like this >>